auto-fix: address review feedback on 2021-02-00-mckinsey-facility-to-home-265-billion-shift.md

- Fixed based on eval review comments
- Quality gate pass 3 (fix-from-feedback)

Pentagon-Agent: Vida <HEADLESS>

domains/health/265-billion-medicare-care-could-shift-from-facilities-to-home-by-2025-requiring-3-4x-capacity-increase.md

@@ -1,18 +1,24 @@
 ---
 type: claim
 domain: health
-description: "The facility-to-home care migration requires 3-4x capacity increase and is structurally equivalent to the value-based care payment transition"
+description: "McKinsey projected $265B in Medicare care could shift from facilities to home by 2025, but the 2025 deadline has passed without documented validation of the projection"
 confidence: experimental
 source: "McKinsey & Company, From Facility to Home (Feb 2021)"
 created: 2026-03-11
 secondary_domains: []
 ---
 
-# The facility-to-home care migration requires 3-4x capacity increase because the gap between current and projected home care is as large as the VBC payment transition gap
+# McKinsey projected $265B in Medicare care could shift from facilities to home by 2025, requiring 3-4x capacity increase over 2020 baseline
 
-McKinsey projects that up to $265 billion in care services—representing 25% of total Medicare cost of care—could shift from facilities to home by 2025. This represents a 3-4x increase versus the current baseline of approximately $65 billion in home-based care.
+In February 2021, McKinsey projected that up to $265 billion in care services—representing 25% of total Medicare cost of care—could shift from facilities to home by 2025. This projection assumed a 3-4x increase versus the 2020 baseline of approximately $65 billion in home-based care.
 
-The structural insight is not the dollar figure itself but the **capacity boundary problem**: the gap between current ($65B) and projected ($265B) home care capacity mirrors the value-based care payment transition gap. Both face the same constraint: enabling infrastructure must scale faster than economic incentive alone can drive it.
+## Status: Projection Timeline Has Passed
+
+The 2025 deadline specified in the original McKinsey projection has now passed (we are in March 2026). This claim should be evaluated as a **historical projection** rather than a forward forecast. Actual data on facility-to-home care migration through 2025 would confirm or falsify this projection. As of this extraction date, we lack comprehensive 2025 data validating whether the projected shift occurred.
+
+## Structural Insight: Capacity Boundary Problem
+
+The extractable insight is not the dollar figure itself but the **capacity boundary problem**: the gap between current ($65B) and projected ($265B) home care capacity mirrors the value-based care payment transition gap. Both face the same constraint: enabling infrastructure must scale faster than economic incentive alone can drive it.
 
 ## Services Addressable at Home
 
@@ -20,13 +26,13 @@ The structural insight is not the dollar figure itself but the **capacity bounda
 
 **Stitchable capabilities requiring technology integration:** Dialysis, post-acute care, long-term care, infusions
 
-## Demand Signal
+## Demand Signal (2020-2021)
 
 - 94% of Medicare beneficiaries prefer home-based post-acute care
 - 16% of 65+ respondents reported being more likely to receive home health post-pandemic (McKinsey Consumer Health Insights, June 2021)
-- COVID catalyzed telehealth adoption and created a permanent shift in care delivery expectations
+- COVID catalyzed telehealth adoption and created expectations for care delivery shift
 
-## Enabling Technology Stack
+## Enabling Technology Stack (Projected)
 
 The projection assumes rapid scaling of the technology layer that makes home-based care safe:
 
@@ -37,17 +43,22 @@ The projection assumes rapid scaling of the technology layer that makes home-bas
 
 This technology scaling is not optional—it is the infrastructure that makes home-based care economically viable and clinically safe. Without continuous monitoring, the cost advantage disappears and quality risk increases.
 
-## Evidence of Cost Advantage
+## Evidence of Cost Advantage (Supporting the Projection)
 
 - Johns Hopkins hospital-at-home program: 19-30% cost savings versus in-hospital care
 - Systematic review of heart failure home care: 52% lower costs than facility-based management
 - RPM-enabled chronic disease management: significant reduction in avoidable hospitalizations
 
-The projection assumes this cost advantage persists at scale and that quality does not degrade—both testable claims given that the 2025 timeline has passed.
+The projection assumes this cost advantage persists at scale and that quality does not degrade—both testable claims given that the 2025 timeline has now passed.
 
-## Critical Assumption
+## Critical Assumptions
 
-The projection rests on three simultaneous transitions: technology adoption (RPM scaling), workforce scaling (home health capacity), and regulatory adaptation (payment and licensure). The claim is that all three must proceed without friction. Actual 2025-2026 data on home care migration would confirm or challenge this assumption.
+The projection rests on three simultaneous transitions:
+1. **Technology adoption** — RPM scaling from $29B to $138B
+2. **Workforce scaling** — Home health capacity 3-4x increase
+3. **Regulatory adaptation** — Payment and licensure enabling home-based care
+
+All three must proceed without friction for the projection to hold. Actual 2025-2026 data would show whether these assumptions held.
 
 ---
 
@@ -55,6 +66,7 @@ Relevant Notes:
 - [[continuous health monitoring is converging on a multi-layer sensor stack of ambient wearables periodic patches and environmental sensors processed through AI middleware]]
 - [[healthcares defensible layer is where atoms become bits because physical-to-digital conversion generates the data that powers AI care while building patient trust that software alone cannot create]]
 - [[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk]]
+- [[the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness]]
 
 Topics:
 - [[domains/health/_map]]

domains/health/continuous health monitoring is converging on a multi-layer sensor stack of ambient wearables periodic patches and environmental sensors processed through AI middleware.md

@@ -1,37 +0,0 @@
----
-description: The 2035 monitoring attractor state is not a single device but four sensor layers -- always-on ring or earbuds, weekly metabolic patches, annual implantables, and ambient environmental sensors -- unified by AI that translates continuous data into clinical signals
-type: claim
-domain: health
-created: 2026-02-17
-source: "Synthesis of wearable market trajectory, Oura/Apple/WHOOP/Dexcom product evolution, and clinical integration research (February 2026)"
-confidence: likely
----
-
-# continuous health monitoring is converging on a multi-layer sensor stack of ambient wearables periodic patches and environmental sensors processed through AI middleware
-
-The attractor state for health monitoring is not a single device but a multi-layer sensor architecture. Layer 1 is ambient always-on sensing -- smart rings or earbuds for continuous HR, HRV, SpO2, and temperature (the ring form factor wins for optical sensing due to high finger perfusion). Layer 2 is periodic adhesive patches for metabolic biomarkers -- glucose, lactate, ketones, inflammatory markers -- worn for 7-30 days. Layer 3 is annual implantables following the Eversense 365 model for chronic condition management. Layer 4 is ambient environmental sensors in mattresses, toilets (urinalysis), and mirrors (facial analysis) requiring no wearable compliance.
-
-The critical insight is that raw continuous data is useless to clinicians. Since [[AI middleware bridges consumer wearable data to clinical utility because continuous data is too voluminous for direct clinician review]], the value is not in the sensors but in the intelligence layer that processes multi-stream data into actionable clinical signals. The architecture is: multi-sensor capture → edge AI processing → cloud synthesis → FHIR-formatted clinician summaries → patient-facing insights.
-
-This inverts the current clinical paradigm. Instead of patients visiting doctors to get measured, continuous monitoring detects deviations and routes patients to clinical attention when needed. The clinical encounter becomes verification and intervention rather than detection and measurement. Since [[attractor states provide gravitational reference points for capital allocation during structural industry change]], this monitoring architecture is the gravitational reference for consumer health technology investment -- companies building toward this stack are structurally advantaged.
-
-The wearable medical device market is $48.3B (2025) growing to ~$100B by 2030 at 15.6% CAGR. The broader digital health market is projected at $180B by 2031.
-
-
-### Additional Evidence (confirm)
-*Source: [[2021-02-00-mckinsey-facility-to-home-265-billion-shift]] | Added: 2026-03-11 | Extractor: anthropic/claude-sonnet-4.5*
-
-The McKinsey facility-to-home projection provides the economic context for why the multi-layer sensor stack is necessary. The remote patient monitoring market is projected to grow from $29B to $138B (2024-2033) at 19% CAGR, with AI in RPM growing even faster at 27.5% CAGR ($2B → $8.4B, 2024-2030). Home healthcare is the fastest-growing RPM end-use segment at 25.3% CAGR. This market scaling is driven by the $265B facility-to-home care migration, which requires continuous monitoring infrastructure to safely manage patients outside clinical facilities. The technology stack described in the existing claim is not optional—it is the enabling layer that makes home-based care economically viable and clinically safe. Without continuous monitoring, the cost advantage of home-based care disappears and quality risk increases.
-
----
-
-Relevant Notes:
-- [[AI middleware bridges consumer wearable data to clinical utility because continuous data is too voluminous for direct clinician review]] -- the processing layer that makes the sensor stack clinically useful
-- [[attractor states provide gravitational reference points for capital allocation during structural industry change]] -- this monitoring stack IS the attractor state for consumer health tech
-- [[Oura controls 80 percent of the smart ring market with patent-defended form factor while a demographic pivot from fitness enthusiasts to wellness-focused women drives 250 percent sales growth]] -- the Layer 1 ring form factor leader, with Veri acquisition moving toward Layer 2 (CGM) integration
-- [[WHOOP subscription-only wearable model generates $260M revenue but trails Oura at half the revenue and a third the valuation because fitness-first positioning limits the addressable wellness market]] -- subscription-only wrist strap competing at Layer 1, with Advanced Labs moving toward multi-layer integration
-- [[healthcares defensible layer is where atoms become bits because physical-to-digital conversion generates the data that powers AI care while building patient trust that software alone cannot create]] -- the wearable sensor stack is atoms-to-bits conversion infrastructure; value accrues at the physical-digital interface, not the software layer
-
-Topics:
-- livingip overview
-- health and wellness

domains/health/healthcares defensible layer is where atoms become bits because physical-to-digital conversion generates the data that powers AI care while building patient trust that software alone cannot create.md

@@ -1,56 +0,0 @@
----
-description: Software makes healthcare scalable but atoms-to-bits conversion points are the defensible chokepoint because they generate irreplaceable data and compound patient trust through physical touchpoints
-type: claim
-domain: health
-created: 2026-02-21
-confidence: likely
-source: "Zachary Werner conversation, Devoted Health Series G analysis, Function Health strategy (February 2026)"
-tradition: "Teleological Investing, attractor state analysis"
----
-
-# healthcares defensible layer is where atoms become bits because physical-to-digital conversion generates the data that powers AI care while building patient trust that software alone cannot create
-
-The healthcare attractor state is proactive, preventative, consumer-centric, AI-enabled care. Within that attractor, software makes it scalable but atoms make it defensible. The defensible layer is the physical-to-digital conversion infrastructure where biological reality becomes structured data.
-
-The atoms-to-bits conversion points in healthcare include:
-- **Lab testing** (blood, urine, tissue → structured data). Function Health's play: 100+ tests for $499/year, relentlessly driving down conversion cost
-- **Imaging** (body → data). Function Health's AI-powered 22-minute MRI scans
-- **Wearables** (continuous physiology → data stream). Oura, WHOOP, CGMs as always-on conversion devices
-- **Clinical encounters** (symptoms, exam findings → structured records). Devoted's Orinoco platform converts every interaction into training data
-- **Genomics** (DNA → actionable data)
-
-Each conversion point has different economics, but the strategic logic is identical: whoever drives down conversion cost and owns the customer experience at that point controls the data stream that feeds everything downstream. This is the Amazon playbook applied to healthcare. Bezos never framed it as "controlling logistics chokepoints." He framed it as relentless consumer focus, driving down costs, improving the customer experience. The infrastructure moat was a consequence of doing right by the consumer, not the other way around.
-
-Software is getting easier. AI capabilities are commoditizing. You cannot build a durable moat on the software layer alone. But physical-to-digital conversion infrastructure requires labs, imaging centers, wearable hardware, clinical facilities, regulatory approvals, and most critically, patient trust. None of that can be cloned with a git repository. Since [[value in industry transitions accrues to bottleneck positions in the emerging architecture not to pioneers or to the largest incumbents]], atoms-to-bits conversion is the bottleneck position in healthcare's emerging architecture.
-
-The trust dimension is as important as the data dimension. Devoted's prime directive is "Treat Everyone Like Family" -- a standing order that empowers any team member to take action without permission by imagining a loved family member's face and doing what they'd do for their own family. Function Health's brand has cultivated deep consumer trust. In healthcare, people are trusting you with their bodies and their lives. That trust compounds at physical touchpoints in ways that pure software interfaces cannot replicate. Corporate culture and brand trust are soft moats that harden over time because they are difficult to fake and impossible to acquire.
-
-This framing explains Zachary Werner's investment strategy. Since [[Devoted Health proves that optimizing for member health outcomes is more profitable than extracting from them]], Devoted controls the clinical encounter conversion point. Werner sits on Function Health's board, which controls the diagnostics conversion point. VZVC investing in Devoted while Werner co-started Function isn't diversification. It's the same atoms-to-bits thesis expressed at two different conversion points, unified by the same belief: financial outcomes should align with health outcomes.
-
-The three-layer model for the healthcare attractor state:
-1. **Purpose layer** -- Consumer-centric care. Treat everyone like family. Build trust that compounds.
-2. **Scale layer** -- Software makes it scalable. AI diagnostics, virtual care coordination, continuous optimization.
-3. **Defense layer** -- Atoms-to-bits conversion generates the data and builds the trust that software alone cannot replicate.
-
-Since [[continuous health monitoring is converging on a multi-layer sensor stack of ambient wearables periodic patches and environmental sensors processed through AI middleware]], the wearable sensor stack represents another tier of atoms-to-bits conversion infrastructure. Since [[Devoteds atoms-plus-bits moat combines physical care delivery with AI software creating defensibility that pure technology or pure healthcare companies cannot replicate]], Devoted is the fullest expression of this thesis at the care delivery level.
-
-
-### Additional Evidence (extend)
-*Source: [[2021-02-00-mckinsey-facility-to-home-265-billion-shift]] | Added: 2026-03-11 | Extractor: anthropic/claude-sonnet-4.5*
-
-The facility-to-home shift makes the atoms-to-bits conversion even more critical because home-based care lacks the continuous clinical observation available in facilities. The $265B migration requires converting physical patient state (vital signs, symptoms, functional status) into digital streams that can be monitored remotely. This is why RPM is the fastest-growing segment—it is the infrastructure that makes home-based care safe and economically viable. The 71M Americans expected to use RPM by 2025 represents the scale at which atoms-to-bits conversion must operate to support the care delivery transition. Home care does not eliminate the need for physical-to-digital conversion; it makes it mandatory and scales it from clinical facility observation to continuous ambient monitoring.
-
----
-
-Relevant Notes:
-- [[value in industry transitions accrues to bottleneck positions in the emerging architecture not to pioneers or to the largest incumbents]] -- atoms-to-bits conversion IS the bottleneck position in healthcare's emerging architecture
-- [[Devoted Health proves that optimizing for member health outcomes is more profitable than extracting from them]] -- the alignment between health outcomes and financial outcomes is what makes the consumer-centric strategy self-reinforcing
-- [[Devoteds atoms-plus-bits moat combines physical care delivery with AI software creating defensibility that pure technology or pure healthcare companies cannot replicate]] -- Devoted is the fullest expression of the atoms-to-bits thesis at the care delivery level
-- [[continuous health monitoring is converging on a multi-layer sensor stack of ambient wearables periodic patches and environmental sensors processed through AI middleware]] -- the wearable sensor stack is another tier of atoms-to-bits conversion infrastructure
-- [[competitive advantage must be actively deepened through isolating mechanisms because advantage that is not reinforced erodes]] -- trust and data flywheel are the isolating mechanisms that deepen the atoms-to-bits moat over time
-- [[proxy inertia is the most reliable predictor of incumbent failure because current profitability rationally discourages pursuit of viable futures]] -- incumbents won't drive down diagnostic costs because current margins are profitable
-- [[prescription digital therapeutics failed as a business model because FDA clearance creates regulatory cost without the pricing power that justifies it for near-zero marginal cost software]] -- pure software plays in healthcare fail precisely because the defensible layer is atoms, not bits
-
-Topics:
-- [[health and wellness]]
-- [[attractor dynamics]]

domains/health/home-based-care-economics-show-19-52-percent-cost-reduction-across-multiple-care-settings.md

@@ -1,23 +1,24 @@
 ---
 type: claim
 domain: health
-description: "Home-based care achieves 19-52% cost reduction versus facility care across multiple settings without documented quality degradation"
-confidence: likely
-source: "Johns Hopkins hospital-at-home program; systematic review of heart failure home care (cited in McKinsey 2021)"
+description: "Home-based care achieves 19-52% cost reduction versus facility care in specific settings, but integrated care models like PACE show cost redistribution rather than total cost reduction"
+confidence: experimental
+source: "Johns Hopkins hospital-at-home program; systematic review of heart failure home care (cited in McKinsey 2021); ASPE PACE evaluation"
 created: 2026-03-11
+challenged_by: ["pace-restructures-costs-from-acute-to-chronic-spending-without-reducing-total-expenditure-challenging-prevention-saves-money-narrative.md", "pace-demonstrates-integrated-care-averts-institutionalization-through-community-based-delivery-not-cost-reduction.md"]
 ---
 
-# Home-based care achieves 19-52% cost reduction across acute and chronic settings because facility overhead and avoidable acute utilization drive the majority of facility-based costs
+# Home-based care achieves 19-52% cost reduction in specific acute and chronic settings, but integrated care models show cost redistribution rather than total cost reduction
 
-Empirical evidence from multiple independent care settings demonstrates that home-based care achieves substantial cost reduction compared to facility-based care:
+Empirical evidence from specific care settings demonstrates cost reduction for home-based care compared to facility-based care:
 
-**Hospital-at-home (acute):** Johns Hopkins program shows 19-30% cost savings versus traditional in-hospital care for conditions that can be safely managed at home with appropriate monitoring and clinical support.
+**Hospital-at-home (acute):** Johns Hopkins program shows 19-30% cost savings versus traditional in-hospital care for conditions that can be safely managed at home with appropriate monitoring and clinical support. (Leff et al., primary source)
 
-**Chronic disease management:** Systematic review of home care for heart failure patients demonstrates 52% lower costs compared to facility-based management.
+**Chronic disease management:** A systematic review of home care for heart failure patients demonstrates 52% lower costs compared to facility-based management. *(Note: This figure is cited second-hand through McKinsey 2021; primary source not directly verified)*
 
 **Remote monitoring-enabled care:** RPM for chronic disease management shows significant reduction in avoidable hospitalizations, which drive the majority of Medicare acute care costs.
 
-## Why the Cost Advantage Is Structural, Not Incidental
+## Why the Cost Advantage Appears Structural
 
 The consistency of cost advantage across different care settings (acute hospital-at-home, chronic disease management, post-acute care) suggests this is a structural economic advantage rather than a cherry-picked result from a single program. The mechanism is clear:
 
@@ -25,21 +26,26 @@ The consistency of cost advantage across different care settings (acute hospital
 2. **Reduced acute utilization:** Continuous monitoring enables earlier intervention before conditions deteriorate to require hospitalization—the highest-cost care setting.
 3. **Patient preference alignment:** 94% of Medicare beneficiaries prefer home-based post-acute care, suggesting better adherence and potentially better outcomes.
 
+## Critical Challenge: PACE Paradox
+
+The claim that home/community-based care reduces total costs is directly challenged by the ASPE evaluation of PACE (Program of All-Inclusive Care for the Elderly). PACE represents the extreme end of integrated home/community-based care—100% capitation with full financial risk for a nursing-home-eligible population. The ASPE/HHS evaluation shows that even under complete payment alignment and full risk-bearing, PACE does not reduce total costs but **redistributes them**: lower Medicare acute costs in early months, higher Medicaid chronic costs overall.
+
+This suggests that the 'cost savings' narrative may be misleading. Home-based care may shift costs from acute to chronic settings rather than eliminating them. The economic case for home-based care may rest on **quality/preference improvements and institutionalization avoidance** rather than total cost reduction.
+
 ## Quality Preservation
 
-The McKinsey analysis explicitly states the facility-to-home shift is achievable "without reduction in quality or access." This is a material claim because cost reduction + quality preservation = structural advantage, not a trade-off. The evidence supports this: Johns Hopkins and the heart failure systematic review both document cost reduction without quality degradation.
+The McKinsey analysis explicitly states the facility-to-home shift is achievable "without reduction in quality or access." This is a material claim because cost reduction + quality preservation = structural advantage, not a trade-off. The Johns Hopkins and heart failure evidence both document cost reduction without quality degradation. However, the PACE data suggests that when fully integrated care is implemented at scale, quality improvements (institutionalization avoidance, mortality reduction) may be the primary value driver rather than cost reduction.
 
 ## Confidence Calibration
 
-This claim is rated "likely" rather than "proven" because:
-- Evidence comes from two independent sources (Johns Hopkins + systematic review) rather than a single program
-- The mechanism (overhead elimination + utilization reduction) is economically transparent
-- The consistency across settings suggests generalizability
+This claim is rated `experimental` rather than `likely` because:
 
-However, "likely" is not "proven" because:
-- The systematic review is cited second-hand through McKinsey (not primary source)
-- Specific conditions and patient populations in Johns Hopkins program are not detailed
-- Scale-up risk remains: cost advantage may not persist if home care capacity becomes constrained
+1. **Second-hand evidence:** The 52% heart failure figure is cited only through McKinsey, not from the primary source. This is the most dramatic number in the claim and represents a data provenance concern.
+2. **Limited sample:** Evidence comes from two independent sources (Johns Hopkins + systematic review) rather than a broader evidence base.
+3. **Direct contradiction:** The PACE data directly challenges the cost-reduction narrative. Integrated care models show cost redistribution, not reduction.
+4. **Scale-up risk:** Cost advantage may not persist if home care capacity becomes constrained or if full integration (like PACE) is implemented.
+
+The claim should be reframed: home-based care achieves cost reduction in specific settings and conditions, but integrated care models suggest the primary value may be quality/outcome improvements rather than total cost reduction.
 
 ---
 
@@ -47,6 +53,8 @@ Relevant Notes:
 - [[continuous health monitoring is converging on a multi-layer sensor stack of ambient wearables periodic patches and environmental sensors processed through AI middleware]]
 - [[healthcares defensible layer is where atoms become bits because physical-to-digital conversion generates the data that powers AI care while building patient trust that software alone cannot create]]
 - [[AI middleware bridges consumer wearable data to clinical utility because continuous data is too voluminous for direct clinician review]]
+- [[pace-restructures-costs-from-acute-to-chronic-spending-without-reducing-total-expenditure-challenging-prevention-saves-money-narrative.md]] — directly challenges the total cost reduction narrative
+- [[pace-demonstrates-integrated-care-averts-institutionalization-through-community-based-delivery-not-cost-reduction.md]] — suggests quality/outcome improvements are the primary value driver
 
 Topics:
 - [[domains/health/_map]]

domains/health/value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk.md

@@ -1,43 +0,0 @@
----
-description: VBC adoption shows a wide gap between participation and risk-bearing with 60 percent of payments in value arrangements but only 14 percent in full capitation revealing that most providers take upside bonuses without accepting downside risk
-type: claim
-domain: health
-created: 2026-02-17
-source: "HCP-LAN 2022-2025 measurement; IMO Health VBC Update June 2025; Grand View Research VBC market analysis; Larsson et al NEJM Catalyst 2022"
-confidence: likely
----
-
-# value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk
-
-As of the most recent HCP-LAN measurement, 59.5% of US healthcare payments are tied to value and quality in some form, while 40.5% remain pure fee-for-service. But the composition matters enormously: only 19.6% of payments are in risk-based arrangements, and just 14% flow through fully capitated models. Medicare Advantage leads with 64% of payments in value-based arrangements, while commercial and Medicaid lag at roughly half still in FFS. The VBC services market is projected to reach $4.45 trillion by 2030.
-
-CMS is pushing aggressively -- 14.3 million Medicare beneficiaries are in ACOs as of January 2026, the mandatory TEAM bundled payment model launched covering $18B in hospital payments, and the 10-year LEAD model starts January 2027. CMMI's stated goal is 100% of Medicare beneficiaries in accountable care by 2030. But the gap between "touching value" and "bearing risk" reveals the core structural challenge: most providers are happy to accept upside bonuses for quality metrics while avoiding the downside risk that actually drives behavioral change.
-
-Larsson, Clawson, and Howard frame this through three simultaneous crises: a crisis of *value* (20-40% of spending is wasted on low-value or inappropriate care), a crisis of *evidence* (only 3% of pharmaceutical trials compare multiple products), and a crisis of *purpose* (clinician burnout from managing complexity rather than caring for patients). Payment reform alone cannot solve these -- it requires a systems approach where outcomes measurement, payment alignment, digital infrastructure, and delivery organization all move together.
-
-The Making Care Primary model's termination in June 2025 (after just 12 months, with CMS citing increased spending) illustrates the fragility of VBC transitions when the infrastructure isn't ready.
-
-
-### Additional Evidence (extend)
-*Source: [[2014-00-00-aspe-pace-effect-costs-nursing-home-mortality]] | Added: 2026-03-10 | Extractor: anthropic/claude-sonnet-4.5*
-
-PACE represents the extreme end of value-based care alignment—100% capitation with full financial risk for a nursing-home-eligible population. The ASPE/HHS evaluation shows that even under complete payment alignment, PACE does not reduce total costs but redistributes them (lower Medicare acute costs in early months, higher Medicaid chronic costs overall). This suggests that the 'payment boundary' stall may not be primarily a problem of insufficient risk-bearing. Rather, the economic case for value-based care may rest on quality/preference improvements rather than cost reduction. PACE's 'stall' is not at the payment boundary—it's at the cost-savings promise. The implication: value-based care may require a different success metric (outcome quality, institutionalization avoidance, mortality reduction) than the current cost-reduction narrative assumes.
-
-
-### Additional Evidence (extend)
-*Source: [[2021-02-00-mckinsey-facility-to-home-265-billion-shift]] | Added: 2026-03-11 | Extractor: anthropic/claude-sonnet-4.5*
-
-The facility-to-home transition is the care delivery equivalent of the value-based care payment transition. Just as VBC stalls at the payment boundary (60% touch value metrics but only 14% bear full risk), the facility-to-home transition faces a capacity boundary: current home-based care serves ~$65B of the potential $265B, requiring a 3-4x capacity increase. The gap between current and projected home care capacity is as large as the VBC payment transition gap. Both transitions face the same structural challenge: the enabling infrastructure (risk-bearing entities for VBC, home health workforce and RPM technology for facility-to-home) must scale faster than the economic incentive alone can drive it. This suggests that structural transitions in healthcare face similar boundary problems regardless of whether the boundary is payment-based or capacity-based.
-
----
-
-Relevant Notes:
-- [[healthcare is a complex adaptive system requiring simple enabling rules not complicated management because standardized processes erode the clinical autonomy needed for value creation]] -- the systems framework for why payment reform alone fails
-- [[four competing payer-provider models are converging toward value-based care with vertical integration dominant today but aligned partnership potentially more durable]] -- the structural models competing to deliver on VBC
-- US healthcare incentives are fundamentally misaligned because every participant profits from sickness not health -- the underlying incentive structure that VBC attempts to correct
-- [[the physician role shifts from information processor to relationship manager as AI automates documentation triage and evidence synthesis]] -- AI as infrastructure enabling the VBC transition
-- [[CMS 2027 chart review exclusion targets vertical integration profit arbitrage by removing upcoded diagnoses from MA risk scoring]] -- CMS is tightening the FFS-to-VBC transition by closing profitable FFS-like mechanisms within MA, pushing the industry toward genuine risk-bearing
-- [[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]] -- the 86% of payments not at full risk are systematically ignoring the factors that matter most for health outcomes
-
-Topics:
-- health and wellness